Trade Name: Glycopyrrolate

Following information is meant for : Wholesalers, Suppliers, Exporters, Doctors, CROs, Comparator Supplies, Hospitals, MOH Tender Supplies, Generic, Brand, Cooperate Sourcing, India, Institutional Buyers.

Manufacturer: Somerset Therapeutics, LLC

Presentation: INJECTION, HUMAN PRESCRIPTION DRUG

Strength: 0.2 mg/mL

Storage and handling

GLYCOPYRROLATE Anticholinergic [EPC],Cholinergic Antagonists [MoA]

Disclaimer
  1. These products are not for sale in US territories. We offer them for exports outside US territories to trade professionals or patients with a valid prescription.
  2. All trademarks, brands and service marks that appear on this website are the property of their respective owners. GNH India does not claim ownership of or any affiliation with, any third party trademarks, brand or service marks appearing on this website.
  3. Third party trademarks are used only for bona fide purposes to identify the products as being that of their respective owners, which constitutes fair use of the trademark under the Trademarks Act, 1999. No sponsorship or endorsement on the part of GNH India should be inferred from the display or use of these trademarks.
  4. Read more

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler, Supplier, Exporters from India of Glycopyrrolate (Glycopyrrolate) which is also known as Glycopyrrolate and Manufactured by Somerset Therapeutics, LLC. It is available in strength of 0.2 mg/mL.

Glycopyrrolate (Glycopyrrolate) is supplied for Tenders, Emergency imports, Un - licensed, Specials, Orphan drug, Name patient line, RLD supplies, Reference listed drugs, Comparator Drug, Bio-Similar, Innovator samples, For Clinical trials. Click to know price.

  • No data
  • Glycopyrrolate Injection is a synthetic anticholinergic agent.
  • Each 1 mL contains:
  • Glycopyrrolate, USP 0.2 mg
  • Water for Injection, USP q.s.
  • Benzyl Alcohol, NF 0.9 % (preservative)
  • pH adjusted, when necessary, with hydrochloric acid and/or sodium hydroxide.
  • For Intramuscular (IM) or Intravenous (IV) administration.
  • Glycopyrrolate is a quaternary ammonium salt with the following chemical name:
  • 3[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl pyrrolidinium bromide.u00a0 The molecular formula is CHBrNO and the molecular weight is 398.33.
  • Its structural formula is as follows:
  • Glycopyrrolate occurs as a white, odorless crystalline powder. It is soluble in water and alcohol, and practically insoluble in chloroform and ether.
  • Unlike atropine, glycopyrrolate is completely ionized at physiological pH values. Glycopyrrolate Injection is a clear, colorless, sterile liquid; pH 2.0 u2013 3.0. The partition coefficient of glycopyrrolate in a n-octanol /water system is 0.304 (log P= -1.52) at ambient room temperature (24u00b0C).
  • Glycopyrrolate, like other anticholinergic (antimuscarinic) agents, inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, exocrine glands and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions.
  • Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases.
  • The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are highly non-polar tertiary amines which penetrate lipid barriers easily.
  • With intravenous injection, the onset of action is generally evident within one minute. Following intramuscular administration, the onset of action is noted in 15 to 30 minutes, with peak effects occurring within approximately 30 to 45 minutes. The vagal blocking effects persist for 2 to 3 hours and the antisialagogue effects persist up to 7 hours, periods longer than for atropine.
  • In Anesthesia:
  • Glycopyrrolate Injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, Glycopyrrolate Injection may be used intraoperatively to counteract surgically or drug - induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants.
  • In Peptic Ulcer:
  • For use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated.
  • Known hypersensitivity to glycopyrrolate or any of its inactive ingredients.
  • In addition, in the management of patients, because of the longer duration of therapy,u00a0 Glycopyrrolateu00a0 Injection may be contraindicated in patients with the following concurrent conditions: glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.
  • This drug should be used with great caution, if at all, in patients with glaucoma.
  • Exposure to excessive amounts of benzyl alcohol has been associated with toxicity (hypotension, metabolic acidosis), particularly in neonates, and an increased incidence of kernicterus, particularly in small preterm infants. There have been rare reports of deaths, primarily in preterm infants, associated with exposure to excessive amounts of benzyl alcohol. The amount of benzyl alcohol from medications is usually considered negligible compared to that received in flush solutions containing benzyl alcohol. Administration of high dosages of medications containing this preservative must take into account the total amount of benzyl alcohol administered. The amount of benzyl alcohol at which toxicity may occur is not known. If the patient requires more than the recommended dosages or other medications containing this preservative, the practitioner must consider the daily metabolic load of benzyl alcohol from these combined sources. (See ).
  • Glycopyrrolate Injection may produce drowsiness or blurred vision. The patient should be cautioned regarding activities requiring mental alertness such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug.
  • In addition, in the presence of fever, high environmental temperature and/or during physical exercise, heat prostration can occur with use of anticholinergic agents including glycopyrrolate (due to decreased sweating), particularly in children and the elderly.
  • Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with Glycopyrrolate Injection would be inappropriate and possibly harmful.
  • No data
  • Anticholinergics,includingu00a0 Glycopyrrolate Injection, can produce certain effects, most of which are extensions of their pharmacologic actions. Adverse reactions may include xerostomia (dry mouth); urinary hesitancy and retention; blurred vision and photophobia due to mydriasis (dilation of the pupil); cycloplegia; increased ocular tension; tachycardia; palpitation; decreased sweating; loss of taste; headache; nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; severe allergic reactions including anaphylactic/anaphylactoid reactions; hypersensitivity; urticaria, pruritus, dry skin, and other dermal manifestations; some degree of mental confusion and/or excitement, especially in elderly persons.
  • In addition, the following adverse events have been reported from post-marketing experience withu00a0 Glycopyrrolate: malignant hyperthermia; cardiac arrhythmias (including bradycardia, ventricular tachycardia, ventricular fibrillation); cardiac arrest;u00a0 hypertension; hypotension; seizures; and respiratory arrest. Post-marketing reports have included cases of heart block and QTc interval prolongation associated with the combined use of glycopyrrolate and an anticholinesterase. Injection site reactions including pruritus, edema, erythema, and pain have also been reported.
  • Glycopyrrolate is chemically a quaternary ammonium compound; hence, its passage across lipid membranes, such as the bloodu2013brain barrier is limited in contrast to atropine sulfate and scopolamine hydrobromide. For this reason the occurrence of CNS-related side effects is lower, in comparison to their incidence following administration of anticholinergics which are chemically tertiary amines that can cross this barrier readily.
  • To combat peripheral anticholinergic, a quaternary ammonium anticholinesterase such as neostigmine methylsulfate (which does not cross the bloodu2013brain barrier) may be given intravenously in increments of 0.25 mg in adults. This dosage may be repeated every five to ten minutes until anticholinergic overactivity is reversed or up to a maximum of 2.5 mg. Proportionately smaller doses should be used in pediatric patients. Indication for repetitive doses of neostigmine should be based on close monitoring of the decrease in heart rate and the return of bowel sounds.
  • If CNS symptoms (e.g., excitement, restlessness, convulsions, psychotic behavior) occur, physostigmine (which does cross the bloodu2013brain barrier) may be used. Physostigmine 0.5 to 2 mg should be slowly administered intravenously and repeated as necessary up to a total of 5 mg in adults. Proportionately smaller doses should be used in pediatric patients.
  • To combat hypotension, administer IV fluids and/or pressor agents along with supportive care.
  • Fever should be treated symptomatically.
  • Following overdosage, a curare-like action may occur, i.e., neuromuscular blockade leading to muscular weakness and possible paralysis. In the event of a curare-like effect on respiratory muscles, artificial respiration should be instituted and maintained until effective respiratory action returns.
  • NOTE: CONTAINS BENZYL ALCOHOL n- u00a0n
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
  • Glycopyrrolate Injection may be administered intramuscularly, or intravenously, without dilution, in the following indications.
  • Glycopyrrolate Injection, 0.2 mg/mL, is available as:
  • 0.2 mg/1 mL Single-dose Vials packaged in 25s (NDC 70069--25)u00a0u00a0
  • 0.4 mg/2 mL (0.2 mg/mL) Single-dose Vials packaged in 25s (NDC 70069--25)u00a0u00a0
  • 1 mg/5 mL (0.2 mg/mL) Multiple-dose Vials packaged in 25s (NDC 70069--25)u00a0
  • 4 mg/20 mL (0.2 mg/mL) Multiple-dose Vials packaged in 10s (NDC 70069--10)u00a0u00a0u00a0
  • Store at 20u00b0C to 25u00b0C (68u00b0F to 77u00b0F) [See USP Controlled Room Temperature].
  • Trademarks are the property of their respective owners.
  • To report SUSPECTED ADVERSE REACTIONS, contact Somerset Therapeutics, LLC at 1-800-417-9175 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
  • Manufactured for:
  • Somerset Therapeutics, LLC
  • Hollywood, FL 33024
  • Made in India
  • Code No.:KR/DRUGS/KTK/28/289/97
  • ST- GLY/P/04
  • Revised: November, 2019
  • 1 mL vial label
  • 1 mL carton label
  • 2 mL vial label
  • 2 mL carton label
  • 5 mL vial label
  • 5 mL carton label
  • 20 ml vial label
  • 20 mL carton label

Ask for Quote

Browse Our Services And Processes

Name Patient Supply

Name Patient Supply

Validated Cold Chain Shipment

Validated Cold Chain Shipment

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

Our Process - The Gnh Way

Our Process - The Gnh Way

Other Pharmaceutical Products

Human Growth Hormone( Somatropin ) - Norditropin Nordiflex 15mg/1.5ml

Human Growth Hormone( Somatropin ) - Norditropin Nordiflex 15mg/1.5ml

Paclitaxel - Abraxane

Paclitaxel - Abraxane

Liposomal Amphotericin - B for Injection IP (AmBisome)

Liposomal Amphotericin - B for Injection IP (AmBisome)

Beclomethasone Dipropionate and Levosalbutamol Inhaler (Aerocort)

Beclomethasone Dipropionate and Levosalbutamol Inhaler (Aerocort)

Monobenzone Cream USP 20% (Albaquin)

Monobenzone Cream USP 20% (Albaquin)

Melphalan Injection IP 50mg (Alkacel)

Melphalan Injection IP 50mg (Alkacel)

Are you an existing customer or a vendor of GNH India? Log in here to